Compare NBHC & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NBHC | GENB |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2011 | 2026 |
| Metric | NBHC | GENB |
|---|---|---|
| Price | $41.40 | $15.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $47.67 | $23.20 |
| AVG Volume (30 Days) | 295.2K | ★ 1.4M |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $47,100,000.00 | N/A |
| Revenue This Year | $39.96 | N/A |
| Revenue Next Year | $7.14 | $16.58 |
| P/E Ratio | $39.73 | ★ N/A |
| Revenue Growth | ★ 2.86 | N/A |
| 52 Week Low | $35.06 | $11.00 |
| 52 Week High | $47.28 | $22.67 |
| Indicator | NBHC | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 41.22 | 49.97 |
| Support Level | $40.47 | $12.05 |
| Resistance Level | $42.74 | $17.46 |
| Average True Range (ATR) | 0.61 | 1.63 |
| MACD | 0.06 | -0.14 |
| Stochastic Oscillator | 51.63 | 12.32 |
National Bank Holdings Corp offers a full range of banking products and financial services to commercial, business, and consumer clients predominantly in Colorado, with a focus on personalized service through relationship managers and banking center associates. The company provides commercial and industrial loans, non-owner occupied commercial real estate loans, Small Business Administration loans as a Preferred Lender Provider, U.S. Department of Agriculture and Farm Service Agency loans, commercial deposit and treasury management products, business online and mobile banking, consumer and residential real estate loans, deposit services, and trust and wealth management services. Its services emphasize full-relationship banking, integrating lending, deposits, and cash management solutions.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.